Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments

Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is shutting down.

CEO Tony Johnson and Chief Financial and Operating Officer Kyle Kuvalanka told Fierce Biotech that the company is closing up shop after failing to secure additional financing. Goldfinch is now in an assignment for the benefit of creditors in Delaware court, an alternative to bankruptcy.